RESUMEN
Primary fungal infection of the central nervous system (CNS) is rare but often associated with severe prognosis. Diagnosis is complicated since cerebrospinal fluid (CSF) samples obtained from lumbar puncture usually remain sterile. Testing for fungal antigens in CSF could be a complementary diagnostic tool. We conducted such measurements in CSF from patients with CNS fungal infection and now discuss the usefulness of ventricular puncture. Mannan and (1â3)ß-D-glucan (BDG) testing were retrospectively performed in CSF samples from three patients with proven chronic CNS fungal infection (excluding Cryptococcus), and subsequently compared to 16 controls. Results from lumbar punctures and those from cerebral ventricles were confronted. BDG detection was positive in all the CSF samples (from lumbar and/or ventricular puncture) from the three confirmed cases. In case of Candida infection, mannan antigen measurement was positive in 75% of the CSF samples. In the control group, all antigen detections were negative (n = 15), except for one false positive. Faced with suspected chronic CNS fungal infection, measurement of BDG levels appears to be a complementary diagnostic tool to circumvent the limitations of mycological cultures from lumbar punctures. In the event of negative results, more invasive procedures should be considered, such as ventricular puncture.
Asunto(s)
Anfotericina B/uso terapéutico , Antifúngicos/uso terapéutico , Antígenos Fúngicos/líquido cefalorraquídeo , Infecciones Fúngicas del Sistema Nervioso Central/líquido cefalorraquídeo , Infecciones Fúngicas del Sistema Nervioso Central/diagnóstico , Infecciones Fúngicas del Sistema Nervioso Central/tratamiento farmacológico , Mananos/líquido cefalorraquídeo , Triazoles/uso terapéutico , beta-Glucanos/líquido cefalorraquídeo , Adulto , Anciano , Biomarcadores/líquido cefalorraquídeo , Líquido Cefalorraquídeo/microbiología , Enfermedad Crónica , Pruebas Diagnósticas de Rutina , Femenino , Voluntarios Sanos , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Central nervous system aspergillosis is relatively rare and difficult to diagnose. Here, we report a case of 90-year-old man with chronic lymphocytic leukemia who presented with a month-long gradually worsening headache followed by 3 days of low-grade fever associated with altered mental status. Aspergillus meningitis diagnosed using Aspergillus galactomannan antigen in the cerebrospinal fluid and treated with voriconazole. Delayed diagnosis and treatment of Aspergillus meningitis is typically associated with high mortality; therefore, it is imperative to include this disease in the differential diagnoses of subacute meningitis.
Asunto(s)
Antígenos Fúngicos/líquido cefalorraquídeo , Aspergilosis/diagnóstico , Mananos/líquido cefalorraquídeo , Meningitis Fúngica/diagnóstico , Anciano de 80 o más Años , Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Diagnóstico Diferencial , Galactosa/análogos & derivados , Humanos , Leucemia Linfocítica Crónica de Células B/complicaciones , Masculino , Meningitis Fúngica/tratamiento farmacológico , Voriconazol/uso terapéuticoRESUMEN
BACKGROUND: Outcomes of childhood hematolymphoid malignancies have improved several fold because of immunosuppressive chemotherapy and broad-spectrum antibiotics for managing febrile neutropenia. An apparent trade-off has been an increase in invasive fungal disease (IFD), affecting multiple organs. We report the diagnostic and therapeutic challenges in 8 children with lymphoid cancers who developed intracranial (IC) fungal abscesses between 2010 and 2017. METHODS: Children below 15 years of age undergoing treatment for leukemia/lymphoma with clinicoradiologic and microbiologic evidence of IC fungal abscess were included. Demographic details, clinical profile, and management were retrospectively audited. Treatment was guided by European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) definitions for IFD with therapeutic drug monitoring (TDM)-directed azole dosing, and surgical intervention. RESULTS: Eight patients (4 B-cell acute lymphoblastic leukemia, 2 relapsed B-cell acute lymphoblastic leukemia, and 2 non-Hodgkin lymphoma) were eligible for analysis. Proven, probable, and possible IFDs were seen in 2 (25%), 4 (50%), and 2 (25%) patients, respectively. Proven IFDs were invasive mucormycosis with remaining having mold infections. Cerebrospinal fluid galactomannan was positive in all 4 patients in whom it was tested. TDM was possible in 5/8 (63%) patients. Antifungal therapy was given for a median period of 4.2 months with 5 (63%) patients having complete resolution. Three (37%) patients expired, of which 2 were attributable to IFDs. CONCLUSIONS: IC fungal abscesses in children can cause significant morbidity and mortality in children with hematolymphoid cancers. Evaluation of cerebrospinal fluid galactomannan may help in early diagnosis and therapy. Prolonged antifungal therapy steered by TDM can help achieve resolution in some cases.
Asunto(s)
Antifúngicos/administración & dosificación , Infecciones Fúngicas del Sistema Nervioso Central/tratamiento farmacológico , Linfoma no Hodgkin/tratamiento farmacológico , Mucormicosis/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/tratamiento farmacológico , Adolescente , Antifúngicos/farmacocinética , Infecciones Fúngicas del Sistema Nervioso Central/líquido cefalorraquídeo , Niño , Preescolar , Femenino , Galactosa/análogos & derivados , Humanos , Linfoma no Hodgkin/líquido cefalorraquídeo , Linfoma no Hodgkin/mortalidad , Masculino , Mananos/líquido cefalorraquídeo , Mucormicosis/líquido cefalorraquídeo , Leucemia-Linfoma Linfoblástico de Células Precursoras B/líquido cefalorraquídeo , Leucemia-Linfoma Linfoblástico de Células Precursoras B/mortalidad , Estudios RetrospectivosRESUMEN
Background: Central nervous system (CNS) histoplasmosis is a life-threatening condition and represents a diagnostic and therapeutic challenge. Isolation of Histoplasma capsulatum from cerebrospinal fluid (CSF) or brain tissue is diagnostic; however, culture is insensitive and slow growth may result in significant treatment delay. We performed a retrospective multicenter study to evaluate the sensitivity and specificity of a new anti-Histoplasma antibody enzyme immunoassay (EIA) for the detection of IgG and IgM antibody in the CSF for diagnosis of CNS histoplasmosis, the primary objective of the study. The secondary objective was to determine the effect of improvements in the Histoplasma galactomannan antigen detection EIA on the diagnosis of Histoplasma meningitis. Methods: Residual CSF specimens from patients with Histoplasma meningitis and controls were tested for Histoplasma antigen and anti-Histoplasma immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody using assays developed at MiraVista Diagnostics. Results: A total of 50 cases and 157 controls were evaluated. Fifty percent of patients with CNS histoplasmosis were immunocompromised, 14% had other medical conditions, and 36% were healthy. Histoplasma antigen was detected in CSF in 78% of cases and the specificity was 97%. Anti-Histoplasma IgG or IgM antibody was detected in 82% of cases and the specificity was 93%. The sensitivity of detection of antibody by currently available serologic testing including immunodiffusion and complement fixation was 51% and the specificity was 96%. Testing for both CSF antigen and antibody by EIA was the most sensitive approach, detecting 98% of cases. Conclusions: Testing CSF for anti-Histoplasma IgG and IgM antibody complements antigen detection and improves the sensitivity for diagnosis of Histoplasma meningitis.
Asunto(s)
Anticuerpos Antifúngicos/líquido cefalorraquídeo , Antígenos Fúngicos/líquido cefalorraquídeo , Histoplasmosis/diagnóstico , Técnicas para Inmunoenzimas/métodos , Inmunoglobulina G/líquido cefalorraquídeo , Inmunoglobulina M/líquido cefalorraquídeo , Meningitis Fúngica/diagnóstico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Líquido Cefalorraquídeo/inmunología , Líquido Cefalorraquídeo/microbiología , Niño , Preescolar , Pruebas Diagnósticas de Rutina/métodos , Femenino , Galactosa/análogos & derivados , Humanos , Lactante , Masculino , Mananos/líquido cefalorraquídeo , Persona de Mediana Edad , Estudios Retrospectivos , Sensibilidad y Especificidad , Adulto JovenRESUMEN
Testing cerebrospinal fluid (CSF) for the presence of galactomannan (GM) antigen may help in diagnosing cerebral aspergillosis (CA). However, the use of the CSF GM test as a diagnostic test has been little studied. We evaluated its diagnostic performance by comparing the CSF GM optical density indexes (ODI) at different cutoffs in patients with probable and proven CA to those in patients without CA. Patients from 2 tertiary referral hospitals with suspected CA between 2004 and 2014 and in whom CSF GM ODI had been determined were selected. European Organization for Research and Treatment of Cancer/Invasive Infectious Diseases Study Mycoses Group (EORTC/MSG) definitions of invasive aspergillosis and CA were used, but with the exclusion of the test to be validated (i.e., the CSF GM test) as a microbiological EORTC/MSG criterion. The study population consisted of 44 patients (4 with proven CA, 13 with probable CA, and 27 with no CA). Of the 17 patients with CA, 15 had a CSF GM ODI of ≥2.0. Of 27 patients without CA, 26 had a CSF GM ODI of <0.5 and 1 had a CSF GM ODI of 8.2. When a GM CSF ODI cutoff of 1.0 was used, the sensitivity, specificity, and positive and negative predictive values were 88.2%, 96.3%, 93.8%, and 92.9%, respectively. The same results were found when a CSF GM ODI cutoff of 0.5 or 2.0 was used. Testing GM in CSF has a high diagnostic performance for diagnosing CA and may be useful to diagnose or virtually rule out the infection without the need for a cerebral biopsy.
Asunto(s)
Antígenos Fúngicos/líquido cefalorraquídeo , Antígenos Fúngicos/inmunología , Mananos/líquido cefalorraquídeo , Mananos/inmunología , Neuroaspergilosis/diagnóstico , Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Galactosa/análogos & derivados , Humanos , Masculino , Persona de Mediana Edad , Reproducibilidad de los Resultados , Estudios Retrospectivos , Sensibilidad y Especificidad , Adulto JovenRESUMEN
Central nervous system (CNS) aspergillosis with stroke has a high mortality and poor prognosis generally. We report a 78-years-old woman with diabetes mellitus, who developed invasive paranasal sinus aspergillosis with the orbital apex syndrome on the right side and cerebral infarction caused by intracranial occlusion of the right internal carotid artery. Based on the presence of a mass lesion in the ethmoid sinus extending to the orbital apex on the right side with cranial CT, the mass lesion was surgically removed and the pathological examination of the surgical specimen revealed aspergillus mold. Immediately after surgery, we initiated treatment with voriconazole 200â mg × 2/day intravenously for 38 days, and then via feeding tube for 86 days until the galactomannan-aspergillus antigen level in the cerebrospinal fluid became negative at 132 days. She is alive now for almost two years without relapse of aspergillosis. There is no definitive guideline for management of patients with CNS aspergillosis concerning the length of drug treatment and the method for monitoring the response for treatment. We believe that measurement of the galactomannan-aspergillus antigen level in the cerebrospinal fluid might be a useful way of monitoring the efficacy of treatment for CNS aspergillosis.
Asunto(s)
Antifúngicos/administración & dosificación , Aspergilosis/complicaciones , Aspergilosis/tratamiento farmacológico , Enfermedades del Sistema Nervioso Central/complicaciones , Enfermedades del Sistema Nervioso Central/tratamiento farmacológico , Accidente Cerebrovascular/etiología , Voriconazol/administración & dosificación , Anciano , Antígenos Fúngicos/líquido cefalorraquídeo , Arteriopatías Oclusivas/etiología , Aspergilosis/diagnóstico , Aspergilosis/patología , Biomarcadores/líquido cefalorraquídeo , Arteria Carótida Interna , Enfermedades del Sistema Nervioso Central/diagnóstico , Enfermedades del Sistema Nervioso Central/patología , Complicaciones de la Diabetes , Diagnóstico por Imagen , Femenino , Galactosa/análogos & derivados , Humanos , Infusiones Intravenosas , Mananos/líquido cefalorraquídeo , Enfermedades de los Senos Paranasales/complicaciones , Accidente Cerebrovascular/mortalidad , Sobrevida , Factores de TiempoAsunto(s)
Antígenos Fúngicos , Candida/inmunología , Candida/patogenicidad , Mananos/inmunología , Meningitis Fúngica/diagnóstico , Adulto , Antifúngicos/administración & dosificación , Antifúngicos/farmacología , Antígenos Fúngicos/líquido cefalorraquídeo , Fluconazol/administración & dosificación , Fluconazol/farmacología , Humanos , Masculino , Mananos/líquido cefalorraquídeo , Meningitis Fúngica/tratamiento farmacológico , Resultado del TratamientoRESUMEN
As culture-based methods for the diagnosis of invasive fungal diseases (IFD) in leukemia and hematopoietic SCT patients have limited performance, non-culture methods are increasingly being used. The third European Conference on Infections in Leukemia (ECIL-3) meeting aimed at establishing evidence-based recommendations for the use of biological tests in adult patients, based on the grading system of the Infectious Diseases Society of America. The following biomarkers were investigated as screening tests: galactomannan (GM) for invasive aspergillosis (IA); ß-glucan (BG) for invasive candidiasis (IC) and IA; Cryptococcus Ag for cryptococcosis; mannan (Mn) Ag/anti-mannan (A-Mn) Ab for IC, and PCR for IA. Testing for GM, Cryptococcus Ag and BG are included in the revised EORTC/MSG (European Organization for Research and Treatment of Cancer/Mycoses Study Group) consensus definitions for IFD. Strong evidence supports the use of GM in serum (A II), and Cryptococcus Ag in serum and cerebrospinal fluid (CSF) (A II). Evidence is moderate for BG detection in serum (B II), and the combined Mn/A-Mn testing in serum for hepatosplenic candidiasis (B III) and candidemia (C II). No recommendations were formulated for the use of PCR owing to a lack of standardization and clinical validation. Clinical utility of these markers for the early management of IFD should be further assessed in prospective randomized interventional studies.
Asunto(s)
Antígenos Fúngicos , Trasplante de Células Madre Hematopoyéticas , Leucemia/sangre , Leucemia/líquido cefalorraquídeo , Mananos , Micosis , beta-Glucanos , Antígenos Fúngicos/sangre , Antígenos Fúngicos/líquido cefalorraquídeo , Biomarcadores/sangre , Biomarcadores/líquido cefalorraquídeo , Congresos como Asunto , Unión Europea , Galactosa/análogos & derivados , Leucemia/microbiología , Mananos/sangre , Mananos/líquido cefalorraquídeo , Micosis/sangre , Micosis/líquido cefalorraquídeo , Micosis/diagnóstico , Micosis/terapia , Trasplante Homólogo , beta-Glucanos/sangre , beta-Glucanos/líquido cefalorraquídeoRESUMEN
There exist limitations in the detection of exogenous oligosaccharides due to their polydisperse and diversiform nature, and particularly the interference of endogenous glycosaminoglycans (GAGs). Herein, a surface plasmon resonance (SPR) assay for detecting acidic oligosaccharide sugar chain (AOSC), an anti-Alzheimer's drug candidate, in cerebrospinal fluid (CSF) was developed based on a carbohydrate antigen-antibody interaction. Rabbits were treated with AOSC intravenously and orally at 40 or 200 mg x kg(-1), respectively. CSF samples were collected at given time points for quantitative determination of AOSC concentrations in the CSF using an SPR-based competitive inhibition assay, and the existence of AOSC in the CSF was indicated as a blood-brain barrier (BBB) accessibility index. AOSC concentration as low as 50 ppb (0.05 microg x ml(-1)) was detected in the CSF, with its peak value approaching 2.091 and 3.316 microg x ml(-1) following intravenous and oral administration, respectively. This is the first time the capacity of AOSC to pass through the BBB has been confirmed using SPR-based competitive inhibition immunoassay. Importantly, the accessibility of AOSC to the BBB indicates AOSC has potential therapeutic value for treating neurodegenerative diseases, particular Alzheimer's disease.
Asunto(s)
Barrera Hematoencefálica/fisiología , Mananos/metabolismo , Resonancia por Plasmón de Superficie , Administración Oral , Animales , Anticuerpos Monoclonales/farmacología , Calibración , Femenino , Inyecciones Intravenosas , Mananos/administración & dosificación , Mananos/líquido cefalorraquídeo , Ratones , Ratones Endogámicos BALB C , Conejos , Reproducibilidad de los ResultadosRESUMEN
Cerebrospinal fluid samples from five patients from which Candida cells were cultured were tested for the presence of mannan. Samples from four patients categorized as having proven candidosis reacted positively. Samples from the remaining patient and from patients with other central nervous system infections were negative. Detection of mannan may be valuable in the diagnosis of Candida meningitis.
Asunto(s)
Antígenos Fúngicos/líquido cefalorraquídeo , Candida/aislamiento & purificación , Candidiasis/diagnóstico , Mananos/líquido cefalorraquídeo , Meningitis Fúngica/diagnóstico , Anciano , Biomarcadores/líquido cefalorraquídeo , Candidiasis/líquido cefalorraquídeo , Preescolar , Femenino , Humanos , Recién Nacido , Masculino , Meningitis Fúngica/líquido cefalorraquídeo , Persona de Mediana Edad , Reproducibilidad de los ResultadosRESUMEN
The performance of antibody detection, antigen detection, and Aspergillus genus-specific PCR for diagnosing Aspergillus meningitis was investigated with 26 cerebrospinal fluid (CSF) samples obtained from a single patient with proven infection caused by Aspergillus fumigatus. Immunoglobulin G antibodies directed against Aspergillus were not detected by enzyme-linked immunosorbent assay in CSF or serum. The antigen galactomannan was detected in the CSF 45 days before a culture became positive, and Aspergillus DNA was detected 4 days prior to culture. Decline of the galactomannan antigen titer in the CSF during treatment with intravenous and intraventricular amphotericin B and intravenous voriconazole corresponded with the clinical response to treatment.
Asunto(s)
Aspergilosis/diagnóstico , Meningitis Fúngica/diagnóstico , Micología/métodos , Anciano , Anfotericina B/uso terapéutico , Anticuerpos Antifúngicos/sangre , Anticuerpos Antifúngicos/líquido cefalorraquídeo , Antifúngicos/uso terapéutico , Antígenos Fúngicos/líquido cefalorraquídeo , Aspergilosis/tratamiento farmacológico , Aspergillus fumigatus/efectos de los fármacos , Aspergillus fumigatus/genética , Aspergillus fumigatus/inmunología , ADN de Hongos/líquido cefalorraquídeo , ADN de Hongos/genética , Farmacorresistencia Microbiana , Femenino , Galactosa/análogos & derivados , Humanos , Mananos/líquido cefalorraquídeo , Mananos/inmunología , Meningitis Fúngica/tratamiento farmacológico , Reacción en Cadena de la Polimerasa , Pirimidinas/uso terapéutico , Factores de Tiempo , Triazoles/uso terapéutico , VoriconazolRESUMEN
The authors report the case of a previously healthy patient who had recurrent cerebral granulomas and meningitis caused by Candida albicans 15 years after the first onset. A combination of external drainage of cerebrospinal fluid (CSF) and intraventricular and intravenous chemotherapy with antifungal agents resulted in a favorable outcome. Investigation of this patient revealed no immunological dysfunction, lymphoproliferative disorder, or candidicidal defect of peripheral blood leukocytes. Sequential measurement of Candida mannan antigen in CSF was useful for establishing the early diagnosis of cerebral candidiasis and for judging the effect of our antifungal chemotherapy. In determining the surgical indications and timing of placement of a ventriculoperitoneal or ventriculoatrial shunt for meningitis subsequent to hydrocephalus after candidal infection, it is better to confirm normal concentrations of the mannan antigen in the CSF repeatedly for more than a week and to determine that cultures of the CSF are negative for Candida albicans.